Grützner and colleagues demonstrate that in BRAF-mutated melanoma, RIG-I agonist-induced cancer immunotherapy combined with standard-of-care MAP kinase pathway inhibitors dabrafenib and trametinib outperforms the individual therapeutic efficacy of each inhibitor. This evidence concerns the gene RIGI and melanoma.